We share our outcomes with you

Choosing where to bring your child for care is a major decision. We understand you want all the information you can get. And you want it in a clear, straightforward form that helps you make the right choice for your family.

That’s why we share our outcomes with you. In medicine, “outcomes” measure the end results of a treatment. By comparing our outcomes with those of other hospitals, locally and nationally, you can see how we rank in terms of keeping patients safe and healthy.

See how Children’s ranks on six quality of care measures. Learn more.

We’re changing the face of epilepsy care

At Children’s, we focus on research and innovations that make a difference at the bedside. From improving day-to-day quality of life for children and teens, to developing new pain management approaches and adopting cutting-edge technologies, our research is completely kid- and family-focused.
Children’s is engaged in many types of research, including investigator-initiated studies (led by a Children’s employed or independent clinician), as well as externally sponsored multicenter trials, observational studies and registries.
Research studies are ongoing in all areas of the hospital and clinics, but read more about epilepsy research below.

Ongoing research and clinical trials

  • Tuberous sclerosis complex natural history database project. (Tuberous Sclerosis Alliance)
  • Safety, tolerability, and pharmacokinetics of Lacosamide oral solution (syrup) as adjunctive therapy in children with partial-onset seizures.
  • Safety, tolerability, and efficacy of long-term oral Lacosamide in children with partial-onset seizures.
  • Treatment of patients with subependymal giant cell astrocytomas (SEGA) associated with Tuberous Sclerosis Complex (TSC).
  • Treatment of angiomyolipoma in patients with either Tuberous Sclerosis Complex (TSC) or sporadic lymphangioleiomyomatosis (LAM).
  • A randomized, double-blind, placebo-controlled study of the safety and efficacy of intranasal midazolam (USL261) in the outpatient treatment of subjects with seizure clusters. ARTEMIS-1 acute rescue therapy in epilepsy with midazolam intranasal spray-1.
  • An open-label safety study of USL261 in the Outpatient Treatment of Subjects with Seizure Clusters.
  • Open-label, single-arm, multicenter, long-term follow-up study to evaluate safety and efficacy of brivaracetam used as adjunctive treatment in pediatric subjects with epilepsy.
  • Topical rapamycin to erase angiofibromas in TSC – multicenter evaluation of novel therapy (The TREATMENT Trial). (University of Texas Medical School at Houston/Mary Kay Koenig, MD)
  • A three-arm, randomized, double-blind, placebo-controlled study of the efficacy and safety of two trough ranges of everolimus as adjunctive therapy in patients with tuberous sclerosis complex (TSC) who have refractory partial-onset seizures.
  • VNS therapy automatic magnet mode outcomes Study in Epilepsy Patients Exhibiting Ictal Tachycardia.

Recently published research

  • “Resource Utilization in Children with Tuberous Sclerosis Complex and Associated Seizures: A Retrospective Chart Review Study.” Journal of Child Neurology. April 2013.
  • “Everolimus for Angiomyolipoma Associated with Tuberous Sclerosis Complex or Sporadic Lymphangioleiomyomatosis (EXIST-2): A Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial. Lancet. January 2013.
  • “Diverse Seizure Presentation of Acute Mycoplasma Pneumoniae Encephalitis Resolving With Immunotherapy.” Journal of Child Neurology. March 2013.
  • “Corpus Callosotomy in Children with Dravet Syndrome and SCN1A Abnormality.” [abstract] Presented at the International League Against Epilepsy meeting, Montreal, Canada June 23-27, 2013.
  • “Duration of Epilepsy Versus Age at Time of Surgery in Predicting Post-Operative Cognitive Outcome.” [abstract] Presented at the International League Against Epilepsy meeting, Montreal, Canada June 23-27, 2013.



At Children’s, we know how important reliable information about conditions and illnesses is.